Cincinnati Children ’s inks biggest commercialization deal ever

Cincinnati Children ’s officials disclosed today that research on gene therapy for sickle cell disease has resulted in the hospital’s biggest commercialization deal ever. The hospital and Roivant Sciences launched as a joint venture a biopharmaceutical company called Aruvant Sciences, which will focus on developin g innovative gene therapies for hematological conditions such as sickle cell and beta thalassemia. Financial terms weren’t disclosed, but the deal includes “a very large upfront…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news